GW441756是一种原肌球蛋白受体激酶A（TrkA；IC50=2nM）抑制剂，同时对LRRK2（IC50=2.2μM）也有抑制作用。
Cas No.:504433-23-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
GW441756 is a potent inhibitor of tropomyosin receptor kinase A (TrkA) with an IC₅₀ of 2nM, and GW441756 also exhibits inhibitory activity against leucine-rich repeat kinase 2 (LRRK2) with an IC₅₀ of 2.2µM[1-2]. By inhibiting the TrkA receptor, GW441756 blocks the nerve growth factor (NGF) signaling pathway, thereby affecting cell proliferation, differentiation, and apoptosis, and can increase caspase-3 levels to induce apoptosis. GW441756 can be used in cancer research and neurobiology studies[3-4].
In vitro, RD-ES and SK-ES-1 Ewing's sarcoma cells were treated with GW441756 (0-15µM) for 72 hours. GW441756 significantly inhibited cell proliferation. When used in combination with the TrkB-selective inhibitor Ana-12, GW441756 produced a more robust anti-proliferative effect than either inhibitor alone[5]. PC12 cells were pretreated with GW441756 (1µM) for 4 hours, followed by stimulation with nerve growth factor (NGF; 50ng/mL) for 24 hours. GW441756 completely inhibited NGF-induced neurite outgrowth and blocked the enhancing effect of Rivastigmine on neurite growth[6].
In vivo, in a CLP-induced sepsis model, mice received intraperitoneal injections of GW441756 (10mg/kg/day) for 22 days, starting 2 days before surgery. GW441756 completely abolished the protective effects of amitriptyline against neuronal loss, gliosis, cognitive dysfunction, and oxidative stress, and blocked amitriptyline's regulation of the Akt/GSK3β signaling pathway and caspase-3 expression[7]. In a rat model of chronic post-surgical pain induced by skin/muscle incision and retraction (SMIR), GW441756 (1-100µM; 10µl) was administered intrathecally once daily from day 10 to day 14 after surgery. GW441756 significantly alleviated mechanical allodynia and suppressed the upregulation of Nav1.7, SGK1, and p-Nedd4-2 proteins in the dorsal root ganglion[8].
References:
[1] Zhao F, Zou X, Li S, et al. BmK NSPK, a Potent Potassium Channel Inhibitor from Scorpion Buthus martensii Karsch, Promotes Neurite Outgrowth via NGF/TrkA Signaling Pathway. Toxins (Basel). 2021 Jan 5;13(1):33.
[2] Wood ER, Kuyper L, Petrov KG, et al. Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7.
[3] Iimura A, Nishida E, Kusakabe M. Role of TrkA signaling during tadpole tail regeneration and early embryonic development in Xenopus laevis. Genes Cells. 2020 Feb;25(2):86-99.
[4] Zhang J, Liu H, Zhang W, et al. Identification of lncRNA-mRNA Regulatory Module to Explore the Pathogenesis and Prognosis of Melanoma. Front Cell Dev Biol. 2020 Dec 17;8:615671.
[5] Heinen TE, Dos Santos RP, da Rocha A, et al. Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma. Oncotarget. 2016 Jun 7;7(23):34860-80.
[6] Terada K, Migita K, Matsushima Y, et al. Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors. PLoS One. 2018 Dec 17;13(12):e0209250.
[7] Zhang L, Peng X, Ai Y, et al. Amitriptyline Reduces Sepsis-Induced Brain Damage Through TrkA Signaling Pathway. J Mol Neurosci. 2020 Dec;70(12):2049-2057.
[8] Liu BW, Zhang J, Hong YS, et al. NGF-Induced Nav1.7 Upregulation Contributes to Chronic Post-surgical Pain by Activating SGK1-Dependent Nedd4-2 Phosphorylation. Mol Neurobiol. 2021 Mar;58(3):964-982.
GW441756是一种原肌球蛋白受体激酶A（TrkA；IC50=2nM）抑制剂，同时对LRRK2（IC50=2.2μM）也有抑制作用[1-2]。GW441756通过抑制TrkA受体来阻断神经生长因子（NGF）信号通路，从而影响细胞增殖、分化和凋亡，并可增加caspase-3并诱导细胞凋亡。GW441756可用于癌症研究和神经生物学研究[3-4]。
在体外，GW441756（0-15μM）处理RD-ES和SK-ES-1尤文肉瘤细胞72小时。GW441756能显著抑制细胞增殖。GW441756与TrkB选择性抑制剂Ana-12联合使用时，GW441756可产生比单一抑制剂更强的抗增殖效果[5]。GW441756（1μM）预处理PC12细胞4小时，随后以神经生长因子NGF（50ng/mL）刺激24小时。GW441756完全抑制神经生长因子诱导的神经突生长，同时阻断Rivastigmine对神经突生长的增强效应[6]。
在体内，在CLP诱导的脓毒症模型小鼠手术前2天，GW441756（10mg/kg/天）连续腹腔注射小鼠22天。GW441756完全消除了阿米替林对神经元丢失、胶质增生、认知功能障碍和氧化应激的保护作用，并阻断了阿米替林对Akt/GSK3β信号通路和caspase-3表达的调节[7]。GW441756（1-100μM; 10μl）每天鞘内注射一次，用于处理SMIR（皮肤/肌肉切口和牵拉）手术诱导的慢性术后疼痛模型大鼠，从手术后第10天持续处理至第14天。GW441756显著减轻了机械性痛觉过敏，并抑制了背根神经节中Nav1.7、SGK1和p-Nedd4-2的表达上调[8]。
| Cell experiment [1]: | |
Cell lines | RD-ES and SK-ES-1 (human Ewing sarcoma cell lines) |
Preparation Method | RD-ES and SK-ES-1 cells were treated with a range of doses of the specific TrkA receptor inhibitor GW441756 (0-15µM) for 72 hours. |
Reaction Conditions | 0-15µM; 72 hours. |
Applications | GW441756 significantly reduced the proliferation of SK-ES-1 cells at all doses tested (IC₅₀=1.13µM) and reduced proliferation of RD-ES cells at doses of 1µM and above (IC₅₀=1.94µM). Furthermore, combined treatment of GW441756 with the TrkB selective inhibitor Ana-12 at low concentrations (0.1µM and 1µM) produced a more robust inhibition of cell proliferation than either inhibitor alone in both cell lines. |
| Animal experiment [2]: | |
Animal models | Adult male Sprague Dawley rats with skin/muscle incision and retraction (SMIR)-induced chronic post-surgical pain |
Preparation Method | An intrathecal catheter was implanted for drug delivery. The specific TrkA inhibitor GW441756 (1-100μM; 10μl) was administered intrathecally once daily from day 10 to day 14 after SMIR surgery. Behavioral tests (mechanical paw withdrawal threshold) were conducted. |
Dosage form | 1-100μM; 10μl; intrathecal injection; once daily for 5 consecutive days. |
Applications | Repeated administration of GW441756 significantly reversed mechanical allodynia in SMIR rats with cumulative analgesic effects and without tolerance. GW441756 also suppressed the surgery-induced upregulation of Nav1.7, SGK1, and phospho-Nedd4-2 (p-Nedd4-2) proteins in the dorsal root ganglion (DRG). |
References: | |
| Cas No. | 504433-23-2 | SDF | |
| 化学名 | (3Z)-3-[(1-methylindol-3-yl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one | ||
| Canonical SMILES | CN1C=C(C2=CC=CC=C21)C=C3C4=C(C=CC=N4)NC3=O | ||
| 分子式 | C17H13N3O | 分子量 | 275.3 |
| 溶解度 | ≥ 13.75mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6324 mL | 18.162 mL | 36.324 mL |
| 5 mM | 726.5 μL | 3.6324 mL | 7.2648 mL |
| 10 mM | 363.2 μL | 1.8162 mL | 3.6324 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet